The International Menopause Society - SFOG

More documents

Recommendations

Info

Mean breast density (%) Mammographic density – Digitized quantification 30 25 20 15 10 5 0 Placebo ALD 0.1 ALD 0.25 Screening Week 24 No significant difference between groups
Breast related adverse events in the whole CHOICE trial by system organ class ALD 0.25 ALD 0.1 Placebo System organ class MedDRA preferred term N (%) E N (%) E N (%) E Breast disorders • Breast discomfort 1 (1%) 1 • Breast pain 2 (1%) 2 2 (1%) 2 1 (1%) 1 • Breast tenderness 1 (1%) 1 1 (1%) 1 4 (2%) 4
Page 1 and 2: HRT idag och i morgon: mot lägre d
Page 3 and 4: jan-00 jul-00 jan-01 jul-01 jan-02
Page 5 and 6: Djup förtroendekris Risker och sä
Page 7 and 8: Postmenopausal Hormone Therapy: an
Page 9 and 10: ERT vs HRT Progestin related side e
Page 11 and 12: No uterus no problem !
Page 14 and 15: Progesterone and progestins can rea
Page 16 and 17: Secreted VEGF in T47-D cells in res
Page 18 and 19: Breast stimulation a class effect
Page 20 and 21: HRT utan bröstpåverkan Är det m
Page 22 and 23: change in density from different pr
Page 24 and 25: Vaginal Maturation Index Placebo 10
Page 26 and 27: Mean number NUMBER OF MODERATE TO S
Page 30: Testosterone addition inhibits estr
Page 33 and 34: Tibolone and BC risk in healthy wom
Page 35 and 36: MLS 10 µg LNG/day Mirena 20 µg LN
Page 37 and 38: Raloxifene
Page 39: BZA 20 mg/ CEE 0.45 mg a 2 year RCT
Page 42 and 43: Mammary Gland Branching in Ducts fr
Page 44 and 45: Options for breast safety Regim VMS

The International Menopause Society - SFOG

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?